Outcomes of treatment with nucleos
For the study, researchers used data from the REAL-B consortium and reviewed the medical records of 3,388 treatment-naive adult hepatitis B patients (1,250 women; 2,138 men) who were started on entecavir or tenox Fuweir treatment.
Propensity score matching (PSM) was applied to balance background characteristics of male and female patients, while competing risk analysis was used to estimate incidence and subdistribution hazard ratios (SHRs) of outcomes, including viral suppression, biochemical response, complete response, and hepatocellular carcinoma (HCC) incidence.
Compared with men, women were older (52.0 years vs 48.6 years) and more likely to be overweight/obese (49.3% vs 65.7%), have diabetes (9.9% vs 13.1%) or cirrhosis (27.9% vs 33.0%). Small. Additionally, HBV DNA was significantly lower in women (5.9 vs 6.0 log10 IU/mL) Alanine aminotransferase (ALT) levels (91 vs. 102 IU/L; p<0.01 for all comparisons).
After PSM, the relevant background characteristics of the two groups became balanced.
In terms of treatment outcomes, female patients had significantly lower biochemical response rates (84.0% vs 90.9%; p<0.001) and complete response rates (78.8% vs 83.4%; p=0.016) compared with male patients. However, there were no significant differences in the 5-year cumulative viral suppression rate (91.3% vs 90.3%; p=0.40) and HCC incidence (5.1% vs 4.4%; p=0.64).
Further analysis showed that men were more likely to achieve biochemical response (SHR, 1.31, 95% confidence interval (CI), 1.17–1.46; p<0.001) and clinical remission (SHR, 1.31) and clinical remission (SHR, 1.31), respectively. out 31% and 16%. 1.16, 95% CI, 1.03-1.31; p=0.016).